Global Inflammatory Bowel Disease (IBD) Diagnostic Market Size (2024 - 2029)

The inflammatory bowel disease (IBD) diagnostic market is projected to experience growth driven by an increasing prevalence of IBD and a rising demand for early diagnosis. The market's expansion is supported by strategic initiatives from key players, such as product launches and mergers. However, challenges such as limited public awareness and stringent regulatory requirements may hinder the market's growth trajectory. The impact of the COVID-19 pandemic, which led to delayed diagnoses, has also affected market dynamics.

Market Size of Global Inflammatory Bowel Disease (IBD) Diagnostic Industry

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
IBD Diagnostic Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 3.88 Billion
Market Size (2029) USD 4.67 Billion
CAGR (2024 - 2029) 3.78 %
Fastest Growing Market Asia-Pacific
Largest Market North America

Major Players

IBD Diagnostic Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Inflammatory Bowel Disease Diagnostic Market Analysis

The Global Inflammatory Bowel Disease Diagnostic Market size is estimated at USD 3.88 billion in 2024, and is expected to reach USD 4.67 billion by 2029, growing at a CAGR of 3.78% during the forecast period (2024-2029).

The COVID pandemic and statewide lockdown have had a major impact on patients with inflammatory bowel disease (IBD), including delayed diagnosis and problems getting healthcare. According to the study titled "Reduction in Inflammatory Bowel Disease Healthcare During the Coronavirus Disease 2019 Pandemic: A Nationwide Retrospective Cohort Study" published in the Gastroenterology in February 2021, IBD diagnoses dropped by 6.5% during the COVID-19 pandemic, with a maximum drop of 46.3%. The number of additional infection-related complications has increased along with COVID-19 prevalence. A report by the Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD) database in January 2022, indicated that among patients with IBD, adverse COVID-19 outcomes were related to age and other co-morbidities. Thus, the decline in the IBD diagnosis during COVID-19 significantly hampered the market growth.

The market is driven by the rise in the prevalence of IBD, the growing need for early diagnosis of IBD, and product launches by the key market players. According to a report by the Centers for Disease Control and Prevention (CDC) published in April 2021, on World IBD Day (May 19), about 7 million around the world suffer from IBD. The report also stated that the rate of prevalence of the disease has significantly increased during the last two decades. Thus, the growing prevalence of the IBD is anticipated to drive the demand for its diagnosis thereby boosting the market. Additionally, according to the study titled "Temporal trends in the epidemiology of inflammatory bowel diseases in the public healthcare system in Brazil: A large population-based study" by Aderson O.M.C. Damiao, published in June 2022, in Brazil, the prevalence of ulcerative colitis and crohn's disease rose from 30.0 per 100,000 in 2012 to 100.1 per 100,000 in 2020 and 15.7 to 56.5 per 100,000 in 2012 to 12.6 to 33.7 per 100,000 in 2020 respectively. Thus, the growing prevalence of IBD diseases such as crohn's disease and ulcerative colitis is anticipated to drive the demand for its diagnosis thereby boosting segment growth.

Additionally, the market growth is supported by several strategies used by the major market players, including product launches, mergers, and acquisitions. For instance, in November 2021, Medtronic plc received the United States Food and Drug Administration (FDA) clearance for its PillCam Small Bowel 3 system for remote endoscopy procedures.

The market is anticipated to grow as a result of the rising demand for IBD diagnoses. However, it is anticipated that the lack of public awareness and strict regulations for entry may impede the market's expansion.

Inflammatory Bowel Disease Diagnostic Industry Segmentation

As per the scope of this report, inflammatory bowel disease (IBD) is characterized by chronic inflammation of the gastrointestinal (GI) tract. The two classifications of IBD are Crohn's disease and ulcerative colitis. Prolonged inflammation can cause damage to the GI tract. The inflammatory Bowel Disease (IBD) Diagnostic Market is segmented by Diagnostics (Blood Tests, Fecal Tests, Endoscopy, Biopsy and Others), Disease Type (Ulcerative Colitis, Crohn's Disease), End User (Hospitals, Diagnostic Laboratories, Others End User), Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). The report offers values (in USD) for the above segments.

By Test Type
Blood Test
Fecal Test
Endoscopy
Biopsy
Others
By Diseases Type
Ulcerative Colitis
Crohns Disease
By End User
Hospitals
Diagnostic Laboratories
Others End User
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Global Inflammatory Bowel Disease (IBD) Diagnostic Market Size Summary

The Inflammatory Bowel Disease (IBD) diagnostic market is poised for significant growth, driven by the increasing prevalence of IBD and the rising demand for early diagnosis. The market is experiencing a resurgence following the disruptions caused by the COVID-19 pandemic, which had led to delayed diagnoses and challenges in accessing healthcare. The pandemic's impact was notably severe, with a substantial drop in IBD diagnoses, which has since prompted a renewed focus on improving diagnostic capabilities. Key market players are actively launching new products and employing strategies such as mergers and acquisitions to enhance their offerings and expand their market presence. The adoption of advanced diagnostic techniques, such as capsule endoscopy, is further propelling market growth by providing high-resolution imaging for conditions like Crohn's disease.

North America, particularly the United States, dominates the IBD diagnostic market, supported by a high prevalence of IBD and a strong demand for early diagnosis. The region's market growth is bolstered by ongoing product launches and the presence of major market players. The market is characterized by its competitive landscape, with several key players holding significant market shares. Innovations in diagnostic tools, such as the FDA-approved Buhlmann fCal Turbo assay, are enhancing disease monitoring and differential diagnosis, contributing to market expansion. The fragmented nature of the market, with numerous players like DiaSorin S.p.A, Quidel Corporation, and American Laboratory Products Company, underscores the dynamic and competitive environment in which these companies operate.

Explore More

Global Inflammatory Bowel Disease (IBD) Diagnostic Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Increasing Prevalence of Inflammatory Bowel Diseases

      2. 1.2.2 Increased Demand for Early Diagnosis

    3. 1.3 Market Restraints

      1. 1.3.1 Lack of Awareness Among People

      2. 1.3.2 Stringent Product Approval Process

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION (Market Size by Value - USD)

    1. 2.1 By Test Type

      1. 2.1.1 Blood Test

      2. 2.1.2 Fecal Test

      3. 2.1.3 Endoscopy

      4. 2.1.4 Biopsy

      5. 2.1.5 Others

    2. 2.2 By Diseases Type

      1. 2.2.1 Ulcerative Colitis

      2. 2.2.2 Crohns Disease

    3. 2.3 By End User

      1. 2.3.1 Hospitals

      2. 2.3.2 Diagnostic Laboratories

      3. 2.3.3 Others End User

    4. 2.4 Geography

      1. 2.4.1 North America

        1. 2.4.1.1 United States

        2. 2.4.1.2 Canada

        3. 2.4.1.3 Mexico

      2. 2.4.2 Europe

        1. 2.4.2.1 Germany

        2. 2.4.2.2 United Kingdom

        3. 2.4.2.3 France

        4. 2.4.2.4 Italy

        5. 2.4.2.5 Spain

        6. 2.4.2.6 Rest of Europe

      3. 2.4.3 Asia-Pacific

        1. 2.4.3.1 China

        2. 2.4.3.2 Japan

        3. 2.4.3.3 India

        4. 2.4.3.4 Australia

        5. 2.4.3.5 South Korea

        6. 2.4.3.6 Rest of Asia-Pacific

      4. 2.4.4 Middle East and Africa

        1. 2.4.4.1 GCC

        2. 2.4.4.2 South Africa

        3. 2.4.4.3 Rest of Middle East and Africa

      5. 2.4.5 South America

        1. 2.4.5.1 Brazil

        2. 2.4.5.2 Argentina

        3. 2.4.5.3 Rest of South America

Global Inflammatory Bowel Disease (IBD) Diagnostic Market Size FAQs

The Global Inflammatory Bowel Disease Diagnostic Market size is expected to reach USD 3.88 billion in 2024 and grow at a CAGR of 3.78% to reach USD 4.67 billion by 2029.

In 2024, the Global Inflammatory Bowel Disease Diagnostic Market size is expected to reach USD 3.88 billion.

Inflammatory Bowel Disease (IBD) Diagnostic Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)